Although breast cancer is less immunogenic than other solid tumors such as kidney cancer, nonsmall cell lung cancer, or melanoma that benefit from immunotherapy, there is evidence that TNBC is more immunogenic than other breast cancer subtypes with high levels of PD‐L1 expression and tumor‐infiltrating lymphocyte (TIL) penetration in the lesion [6, 7]. This evidence concerns the gene CD274 and breast carcinoma.